Quantitative Computed Tomography in Chronic Obstructive Pulmonary Disease

Lynch, David A. MD; Al-Qaisi, Mustafa A. MD

Journal of Thoracic Imaging:
doi: 10.1097/RTI.0b013e318298733c
Symposium Review Articles
Abstract

Quantitative computed tomography is being increasingly used to quantify the features of chronic obstructive pulmonary disease, specifically emphysema, air trapping, and airway abnormality. For quantification of emphysema, the density mask technique is most widely used, with threshold on the order of-950 HU, but percentile cutoff may be less sensitive to volume changes. Sources of variation include depth of inspiration, scanner make and model, technical parameters, and cigarette smoking. On expiratory computed tomography (CT), air trapping may be quantified by evaluating the percentage of lung volume less than a given threshold (eg, −856 HU) by comparing lung volumes and attenuation on expiration and inspiration or, as done more recently, by coregistering inspiratory and expiratory CT scans. All of these indices correlate well with the severity of physiological airway obstruction. By constructing a 3-dimensional model of the airway from volumetric CT, it is possible to measure dimensions (external and internal diameters and airway wall thickness) of segmental and subsegmental airways orthogonal to their long axes. Measurement of airway parameters correlates with the severity of airflow obstruction and with the history of chronic obstructive pulmonary disease exacerbation.

Author Information

Division of Radiology, National Jewish Health, Denver, CO

Supported by US National Institutes of Health (NIH) COPDGene study, Award Numbers R01HL089897 and R01HL089856 from the National Heart, Lung, And Blood Institute (NHLBI). The COPDGene project is also supported by the COPD Foundation through contributions made to an Industry Advisory Board comprising AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Siemens, and Sunovion. Dr Lynch’s institution and laboratory receives research support from the NHLBI, Siemens Inc., Perceptive Imaging Inc., and Centocor Inc.

Dr Lynch is a consultant to Perceptive Imaging Inc., Boehringer Ingelheim Inc., Genentech Inc., Gilead Inc., and Intermune Inc. The remaining author declares no conflicts of interest.

Reprints: David A. Lynch, MD, Division of Radiology, National Jewish Health, 1400 Jackson Street, Denver, CO 80206 (e-mail: lynchd@njhealth.org).

© 2013 by Lippincott Williams & Wilkins